• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Background Despite improvements in the management of atrial fibrillation, patients with this
condition remain at increased risk for cardiovascular complications. It is unclear whether …

The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a
substantial burden on patients and health care services. Although the management of AF …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Atrial fibrillation is a heart arrhythmia strongly associated with other heart-related
complications that can increase the risk of strokes and heart failure. Manual …

Tobacco smoking continues to be a major risk factor for cardiovascular disease (CVD) and
the leading avoidable cause of death worldwide. Tobacco smoking has declined in high …

Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by
the American Heart Association in response to the high prevalence of metabolic and kidney …